A hybrid vehicle that delivers DNA

November 25, 2014 by Cory Nealon
University at Buffalo researchers, including Charles Jones, far right, a doctoral candidate in the Department of Chemical and Biological Engineering, are developing new technology to improve DNA vaccines. Credit: Onion Studio

A new hybrid vehicle is under development. Its performance isn't measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies.

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

"The technology that we're developing could help take immunization to the next level," said Blaine A. Pfeifer, PhD, an associate professor in the Department of Chemical and Biological Engineering in the School of Engineering and Applied Sciences at the University at Buffalo.

Pfeifer, the study's lead author, added: "By improving the delivery of DNA vaccines, we can potentially harness the human immune system in new ways to fight everything from the flu and herpes to HIV and cancer."

Conventional vaccines, like those used to fight polio and smallpox, are typically composed of an agent that contains weakened or killed forms of the disease-causing microbe. The agent prompts the immune system to recognize the agent as foreign, destroy it, and keep a record of it so the immune system can more effectively fight it in the future.

While effective, some vaccines don't last, others can revert to dangerous forms and some are costly and time-consuming to develop. Furthermore, no effective vaccines exist for cancer, malaria and others diseases that kill millions of people worldwide annually.

DNA vaccines could address these problems.

To create them, researchers analyze disease-causing sources, such as a pathogenic microbe. They then isolate copies of the microbe's genes (usually one or two) responsible for the disease.

The genetically engineered DNA is injected into the body, whereupon being processed by the immune cells, directs the production and presentation of antigens which provoke an capable of destroying the disease.

Essentially, the body's own cells become -making factories that create the antigens necessary to stimulate the immune system, according to the National Institute of Allergy and Infectious Diseases.

In theory, DNA vaccines can generate broad immune responses; they are relatively inexpensive to create; and they can't cause the disease because they don't contain the source of the disease, only a few of its genes. Dozens of clinical trials involving DNA vaccines are underway. Most are investigating treatments for HIV and cancer, while others involve influenza, hepatitis B and C, HPV and malaria.

A problem limiting the effectiveness of some DNA vaccines, however, is that they do not sufficiently stimulate the . Scientists say this is due, in part, to the inefficient delivery of the genes. For example, some travel to the wrong place while others get caught in intracellular traffic jams.

To address the problem, Pfeifer and his students collaborated with Anders Hakansson, PhD, formerly of the UB School of Medicine and Biomedical Sciences, and a senior co-author of the study.

The team combined two delivery vehicles - a bacterial cell and a synthetic polymer - to create a hybrid. Designed to target specific (antigen-presenting cells) and more efficiently deliver genes to the nucleus of those cells, the hybrid outperformed the two individual delivery vehicles when tested in a mouse model.

"The hybrid provided a synergistic boost in delivery effectiveness due to its dual nature," said Charles H. Jones, a doctoral candidate in the Department of Chemical and Biological Engineering at UB and the study's first author. "We also determined that it's relatively inexpensive to create and flexible in terms of use. The results thus far are very encouraging."

The team continues to test the vehicle in different models. The goal, Pfeifer said, is to create a vehicle that will be useful for many DNA vaccines.

Explore further: Making vaccines more effective

More information: Hybrid biosynthetic gene therapy vector development and dual engineering capacity, Charles H. Jones, 12360–12365, DOI: 10.1073/pnas.1411355111

Related Stories

Making vaccines more effective

September 19, 2012
(Medical Xpress)—Scientists have discovered an important mechanism in which a synthetic DNA targets the immune system that could significantly improve the effectiveness of future vaccines.

Protein serves as a natural boost for immune system fight against tumors

January 30, 2014
Substances called adjuvants that enhance the body's immune response are critical to getting the most out of vaccines. These boosters stimulate the regular production of antibodies—caused by foreign substances in the body—toxins, ...

Asthma vaccine discovery

October 6, 2014
With asthma now affecting up to one in four New Zealand children, the researchers say this is a promising step in the challenge to understand and control asthma.

Immune system research also may help reveal new asthma clues

November 6, 2014
A new method of developing vaccines could point the way forward in the fight against infectious diseases for which traditional vaccination has failed, according to a new Rutgers study.

Technique to model infections shows why live vaccines may be most effective

September 18, 2014
Vaccines against Salmonella that use a live, but weakened, form of the bacteria are more effective than those that use only dead fragments because of the particular way in which they stimulate the immune system, according ...

Possibilities for personalised vaccines revealed at ESMO Symposium

November 21, 2014
The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

Recommended for you

Researchers find infectious prions in Creutzfeldt-Jakob disease patient skin

November 22, 2017
Creutzfeldt-Jakob disease (CJD)—the human equivalent of mad cow disease—is caused by rogue, misfolded protein aggregates termed prions, which are infectious and cause fatal damages in the patient's brain. CJD patients ...

Study reveals new mechanisms of cell death in neurodegenerative disorders

November 22, 2017
Researchers at King's College London have discovered new mechanisms of cell death, which may be involved in debilitating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Surprising roles for muscle in tissue regeneration, study finds

November 22, 2017
A team of researchers at Whitehead has illuminated an important role for different subtypes of muscle cells in orchestrating the process of tissue regeneration. In a paper published in the November 22 issue of Nature, they ...

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

New simple test could help cystic fibrosis patients find best treatment

November 21, 2017
Several cutting-edge treatments have become available in recent years to correct the debilitating chronic lung congestion associated with cystic fibrosis. While the new drugs are life-changing for some patients, they do not ...

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.